Results 191 to 200 of about 510,210 (307)
Vitamins could regulate both MMP‐2 and MMP‐9 expression and activity through transcriptional and MAPK signaling pathway modulation. This study highlights the potential of vitamins as low‐toxicity therapeutic or adjunct agents for targeting MMP‐mediated cancer progression. Abstract Matrix metalloproteinases (MMP‐2 and MMP‐9) are key regulators of cancer
Yen Thi Nguyen +5 more
wiley +1 more source
RAD54B as a biomarker for prognosis and immunotherapy response in bladder cancer. [PDF]
Lu Q, Guo J, Xu Y, Cui Y, Han C.
europepmc +1 more source
Cold atmospheric plasma‐mediated tumor microenvironment remodeling for cancer treatment
Schematic presentation of CAP‐mediated TME remodeling. This review summarizes recent efforts in cold atmospheric plasma (CAP) application in cancer treatment, highlighting the anticancer potential of CAP, molecular mechanisms, and future perspectives for further improvement and clinical translation.
Israr Khan +8 more
wiley +1 more source
Identification of a weighted urinary microbial signature for bladder cancer discrimination. [PDF]
Russo F +9 more
europepmc +1 more source
Marine silicon for biomedical sustainability
Schematic illustrating marine silicon for biomedical engineering. Abstract Despite momentous divergence from oceanic origin, human beings and marine organisms exhibit elemental homology through silicon utilization. Notably, silicon serves as a critical constituent in multiple biomedical processes.
Yahui Han +3 more
wiley +1 more source
Targeting the SMAD3/CISD2 axis suppresses bladder cancer progression by promoting ferroptosis in mesenchymal-like bladder cancer cells. [PDF]
Sun Y +6 more
europepmc +1 more source
Drug‐coated balloons: From conventional designs to next‐generation innovations in vascular therapy
This review traces the evolution of drug‐coated balloons (DCBs) from conventional designs to next‐generation platforms. We highlight innovations in balloon engineering, coating technologies, and therapeutic agents that enhance localized drug delivery while addressing challenges in efficiency, safety, and biocompatibility for vascular and emerging non ...
Lu Zhang +5 more
wiley +1 more source
Neoadjuvant Nivolumab with or without Ipilimumab for Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer. [PDF]
Guercio BJ +24 more
europepmc +1 more source

